SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-22-021210
Filing Date
2022-04-22
Accepted
2022-04-22 17:28:42
Documents
14
Period of Report
2022-04-20
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea158727-8k_allarity.htm   iXBRL 8-K 41747
2 PRESS RELEASE DATED APRIL 22, 2022 ea158727ex99-1_allarity.htm EX-99.1 14837
6 GRAPHIC image_001.gif GRAPHIC 2869
  Complete submission text file 0001213900-22-021210.txt   242415

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE allr-20220420.xsd EX-101.SCH 3033
4 XBRL LABEL FILE allr-20220420_lab.xml EX-101.LAB 34476
5 XBRL PRESENTATION FILE allr-20220420_pre.xml EX-101.PRE 22595
8 EXTRACTED XBRL INSTANCE DOCUMENT ea158727-8k_allarity_htm.xml XML 3765
Mailing Address 210 BROADWAY SUITE 201 CAMBRIDGE MA 02139
Business Address 210 BROADWAY SUITE 201 CAMBRIDGE MA 02139 401-426-4664
Allarity Therapeutics, Inc. (Filer) CIK: 0001860657 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41160 | Film No.: 22846802
SIC: 2834 Pharmaceutical Preparations